



**Trinity College Dublin**  
Coláiste na Tríonóide, Baile Átha Cliath  
The University of Dublin

# Health Sciences Faculty Forum: Intensifying Innovation



**Trinity Innovation and Enterprise**

**Gordon Elliott (TTO); Eoin Kieran (TTO); Lyn Markey (Industry)**



**20<sup>th</sup> November 2025**

# Trinity Innovation and Enterprise - Overview



## Innovation & Enterprise Leadership Team





**Michelle Olmstead**  
Chief Innovation & Enterprise Officer



**Neil Gordon**  
Portal  
Director





**Nessa McEniff**  
Learnovate  
Director



**Vincent Coole**  
KnEx  
Director




# KnEx - TTO - Who and Where



1st Floor, the Tower, Trinity East

# Technology Transfer Function, Trinity Innovation & Enterprise



# Knowledge Exchange Office (KnEx) - 3 Years Data



**15 spin-outs**

**9 High Potential Start-ups**

**€100m in investment**



**>350 jobs created by spin-outs**

**22 products and services launched on the market**



**4 spin-out exits worth €730m total**



INFLAZONE

etū



SilverCloud

IdentiGEN



**296 industry collaborations**

**40% with SMEs**



**73 new licences**



**30% underpinning spin-out investment**



**22% to other Irish SMEs**

**167 inventions disclosed by Trinity staff**



**51 patents filed**



**119 consultancy engagements**

**15% with AHSS**



**€11m for 21 EI Commercialisation Fund Projects**



**€80m University Bridge Fund 2**

# Knowledge Transfer (KT) Boost Programme

A **4-year, €33.4 million** Irish Government/ERDF programme to fund and strengthen **innovation** and **Technology Transfer Offices (TTOs)** in **universities** to **boost research commercialisation**.


Key pillar of TCD KTBoost – **Strengthen Sectoral Alliances** with semi-state bodies and other government organisations.

- Access to **Trinity's IP** and research expertise to **co-develop** and **commercialise innovations**.

Funding for new **Knowledge Transfer Case Officer (KTCO)** position to increase KT and KnEx TTO team capacity.

- Dedicated **IP & commercialisation support** through the **KTCO** (Eoin Kieran) for external organisations.

# TCD – IP Alliance Initiative



**Other external organisations –**  
public research, non-university,  
not-for-profit e.g. city / county  
councils, SEAI, Airport authority,  
other transport authorities,  
hospitals.

# IP Alliance Overview

**Purpose:** Extend commercialisation supports to hospital-based innovators **not formally affiliated** with the TCD's schools or research programmes e.g., medical physicists, nurses, physiotherapists, radiologists, non-TCD affiliated doctors, biochemists, pharmacists, occupational therapists, technicians.

**Model:** Knowledge Transfer Case Officer is **embedded** part-time within the **hospitals** to identify, support, and progress medical innovations.

**Scope:** Focus on MedTech innovation, fostering the development of **innovative technologies** and solutions to **enhance patient outcomes** and deliver broader **societal impact**.

## IP & Commercialisation:

- Selected projects' **IP assigned** to TCD, enabling access to **RPO funding** (e.g. Enterprise Ireland, EU).
- TCD leads **IP & commercialisation** through the **KnEx, TTO**.

## Framework Agreements:

- **Draft MoU** and **Draft IP Assignment** and inter-institutional agreement template.

# TCD – IP Alliance – Specific Supports

## **Supports available to hospital-based innovators:**

- 1. Navigate the commercialisation process.**
- 2. IP identification, protection, development and management.**
- 3. IP and commercialisation training.**
- 4. IP questions in funding bids.**
- 5. Advise on IP clauses in legal agreements.**




- Invention Disclosures.
- On-site IP Clinics
- Market assessment and commercial feasibility.
- Development funding (e.g. via Enterprise Ireland).
- Commercialisation strategy development.
- Regulatory guidance.

# Jaw Fracture Repair Device



## Inventors:

- **Maxillofacial Unit, SJH** - Mr Kumara Ekanayake and Dr. Cian Henry
- **Design Innovation Lab, SJH** – Dr. Gerard Boyle, Dr. Chris Soraghan, Conall Casey, Maire Kane
- **2022:** Invention Disclosed.
- **2025 Q1:** Patent Filed.
- **2025 Q2:** Enterprise Ireland (EI) Feasibility Grant €15,000.
- **2025 Q3:** Invited EI Full Commercialisation Fund.



# NOVAP: Novel Device for Ventilator Associated Pneumonia Prevention



Breathing New Life into Ventilator  
Associated Pneumonia Prevention



- **2022:** Invention Disclosed.
- **2023:** Patent Filed.
- **2023:** Enterprise Ireland Commercialisation Fund ~€500k.



Emily Naylor Jones

Co-Founder, Commercial  
Lead, 18 years ICU experience  
in critical care and clinical  
research



Prof. Ignacio Martin  
Loeches

Co-Founder, Clinical Lead



Brooke Tornifoglio,  
PhD

Principle Investigator,  
Assistant Professor in  
Biomedical Engineering in  
the School of Engineering at  
Trinity College Dublin



Agnieszka Witecka,  
PhD

Technical Lead, Research  
Fellow



Eduardo Ruiz-  
Hernández

Technical Advisor, Associate  
Professor in Pharmacy at  
Trinity College Dublin



# Head Diagnostics – iTremor Device



Dr. Gerard Boyle  
Chief Technology Advisory



Dr. Mindaugas Norkus  
Chief Technology Officer



## Irish medtech company signs global licence with Philips

Updated / Thursday, 17 Jul 2025 13:48



- **2014:** Invention Disclosed. Medical Physics and Bio-engineering (MPBE), MISA, SJH.
- **2015:** Enterprise Ireland Commercialisation Fund ~€200K
- **2017:** Enterprise Ireland Commercialisation Fund ~€200K
- **2018:** TCD Campus Company.
- **2025:** Licensing Deal with Philips.

# IP Commercialisation Process at TCD



# Research/Invention – The Building Blocks of Commercialisation


Research generates **Intellectual Property (IP)** - the **raw material** of **commercialisation**.


**IP - results and inventions** arising from **research & development** activities.

- **Results and data.**
- **Technical inventions / technologies.**
- **Databases, algorithms and software.**
- **Distinctive signs / symbols.**
- **Know-how**, processes and methodologies.
- **Copyright works** including presentations, procedures, manuals, training materials and other information outputs.

# Disclosure – Telling us about your Invention

CONFIDENTIAL

 Trinity College Dublin  
Coláiste na Tríonóide, Baile Átha Cliath  
The University of Dublin



**INVENTION DISCLOSURE FORM**

Please send a **SIGNED** electronic version of this Invention Disclosure Form to your Case Manager

## Invention Disclosure Form (IDF) and/or SDF

1. **Technical Description** – summary, problems addressed, existing solutions.
2. **Commercial Applications** – Where?, How?, By whom?
3. **Disclosures** – paper, poster, presentation.
4. **Third Party Property** – any external used?
5. **Literature and Patent Search** – known prior art
6. **Declaration of Inventorship**

# Technology Evaluation – Assessing the Potential

## Patentability

- Can we **protect** it with a **patent**?
- Does the **technology** offer a **better solution** than currently available?

## Market Opportunity

- Is there a large enough market to make the commercial opportunity attractive (to an investor)?
- Market growth?
- Competitive landscape?

## IDF Due Diligence

- IP Ownership - funders, external inventors, other third-party rights?



# Protection – Patents: Securing your Invention

The "**social contract**" implicit in the patent system

**Reveal**  
invention



**Get**  
exclusivity

- **Prevent others** from making, using or selling infringing products in countries where the patent applies.
- Up to **20 years** from filing date.
- **Sell** or **license** these rights.



... so that others can learn from it  
and improve upon it!

# What can be patented?



## Inventions that are...

- **Novel** to the world (no previous public disclosure)
- **Inventive** (i.e. not an "obvious" solution)
- **Industrial application**



# What not to do when considering filing a patent application



- **No publication** prior to filing  
e.g. no article, press release, conference presentation/poster/proceedings or blog entry



- No sale of products incorporating the invention prior to filing



- No lecture or presentation prior to filing  
except under a **non-disclosure agreement** (NDA)



- Seek professional advice soon!
- File before others do!

# Development – “Turning IP into a Market-Ready Solution”



## Enterprise Ireland - Commercialisation Fund

- **Commercialisation Fund *Feasibility (CFF)* €15,000** - validate potential market opportunity before development.
- **Proof of Concept (PoC) €100,000** - validate technology – prototype, disease model data, user studies.
- **Commercialisation Fund (CF) ~€500,000** – Minimum Viable Product → **commercially viable entity**.

## European Funding – Horizon

- **European Innovation Council (EIC)**  
*PathFinder, Transition, Accelerator*
- **European Institute of Innovation and Technology (EIT):**  
Knowledge and Innovation Communities (KICs) e.g. EIT Health





***Mission : To accelerate the transition of outstanding discoveries in Irish biomedical research to commercial success***

- **5-year** programme - January 2025 –Dec 2029
- **€31m** to advance the commercialisation of therapeutics research
- National Programme – Projects funded across 8 universities

**Health Science Faculty projects include:**

- Prof. Anne Marie Healy – School of Pharmacy
- Prof. John Gilmer- – School of Pharmacy
- Prof. Seamus Donnelly - – School of Medicine

**New call for projects – Q1 2026**



## OPERATIONS TEAM

- Prof. Vincent Kelly – Director
- Dr. Araz Raoof – Executive Director
- Dr. Alison Humbles – Senior Portfolio Manager (TCD)
- Dr. Bill McCormack – Bus & Training Manager
- Dr. Aoife Campbell – Portfolio Manager (RCSI)
- Dr. David Loughrey-Portfolio Manager (UCD)
- Cintia Marques Silva – Communications Manager
- Dr. Magda Ghanim - Administration Manager
- Ms. Jacqueline Ballentine-Armstrong - Arc Hub Finance and Operations Manager

To find out more, contact: [archub@tcd.ie](mailto:archub@tcd.ie)

# Marketing – “Finding the Right Partners”

## TrI&E & Wider TCD Networks

- Investors, industry contacts, commercial leads.

## Digital Marketing and Match-making

- **KnEx, TTO – In-Part** software platform.
- Social media promotion.

**IN-PART**

## Conferences and Events

- Recommendations,
- Promotional materials and pitching support.
- Introductions and follow-ups.



Powered by: inpart

### Advanced Liquid Drug Encapsulation Technique

Novel drug encapsulation method enables high drug loading while maintaining thermodynamic stability and rapid dissolution

[Request an introduction](#)

Reference: AH01-882-01

Source: Odu Mazza, <https://stock.adobe.com/uk/1426477567/stock.adobe.com>

#### IP Status

Patent application submitted

## Tech Overview

This invention addresses the critical challenge of poor bioavailability in oral solid dosage forms caused by the low solubility of crystalline active pharmaceutical ingredients (APIs). The technology combines ionic liquids (salts melting below 100°C) of APIs with polymers to create stable solid compositions. By encapsulating the ionic liquid within a polymer matrix (e.g., ethyl cellulose or maltodextrin), the solution enables high drug loading while maintaining thermodynamic stability and rapid dissolution.

The breakthrough lies in overcoming recrystallisation risks associated with amorphous solid dispersions, achieving >90% dissolution in aqueous media without precipitation.

## Stage of Development

Development stage: Lab-validated prototypes (TRL 4–5); spray-dried powders characterised for dissolution, stability, and phase behaviour.

Validation: In vitro dissolution testing in deionised water and simulated intestinal fluid (0.05M phosphate buffer, pH 6.8) confirms >90% release within 10 minutes.

Key milestones: UK patent filed (Application No. 2012897.1, priority date 18 August 2020); ionic liquid synthesis scaled to 47.96g batches (90% yield).

Gaps: No clinical or animal trial data; further in vivo testing required.


## Benefits

*Enhanced solubility and bioavailability:* Ionic liquids eliminate lattice energy barriers, enabling near-complete API dissolution in water and simulated intestinal fluid (pH 6.8) within 10 minutes.

*High drug loading:* Supports up to 75% w/w API content, surpassing amorphous solid dispersions (typically ≤40%).

*Thermodynamic stability:* No crystallisation observed in dissolution media over two years, ensuring consistent performance.

# Licensing – “Transferring Technology to the World”




## How KnEx Supports You:

- **Licensing strategy** development.
- Lead **licensing negotiations** with industry and campus companies.
- Ensure legal compliance and **fair terms** – National IP Protocol.
- Facilitate **spin-out licensing**, including equity, agreements and business plan support.
- **Post-deal management** - licensee relationships and obligations.

## How can IP commercialisation lead to impact?

- ✓ Patented technology developed with and/or licenced to existing company – new/improved product, service or process.
- ✓ TCD technology commercialised through new spin-out company.



- Improved patient outcomes and care.
- Faster development of medical innovations.
- Job creation through start-up companies.
- Increased access to advanced technologies.
- Revenue reinvestment for future R&D.
- Economic growth and societal impact.
- Incentivise involvement in commercialisation.



Silicon Republic

<https://www.siliconrepublic.com> › start-ups


### Dublin's ProVerum bags \$80m for its enlarged prostate ...

26 Aug 2025 — The 2016-founded Trinity College Dublin spin-out is behind ProVee, a minimally invasive solution for treating benign prostatic hyperplasia.

# Case Example: SelfSense Technologies – SmartSplint



- **School of Dental Sciences.**
- Dr. Padraig McAuliffe and Dr. Brian O'Connell.
- Device to detect bruxism (teeth-grinding).
- TCD Campus Company.



Business

## Smart mouthguard to tackle dental wear and tear

Mouthguard sends information on grinding to dentist and smartphone

Expand



# Case Example: VertiGenius

- **School of Medicine.**
- Dr. Dara Meldrum – physiotherapist.
- Device for vestibular rehabilitation.
- Enterprise Ireland Commercialisation Fund.
- Joint RCSI/TCD Campus Company.

## Vertigenius secures €2.1m investment for breakthrough vertigo medtech

 **John Kennedy** May 8, 2024

Vertigenius has developed a wearable head sensor and software that can improve the treatment of vertigo.



# Case Example: ProACT

- **School of Nursing and Midwifery.**
- Dr. John Dinsmore
- Horizon Europe funded.
- Integrated Technology Ecosystems for ProACTIVE Patient Centred Care
- Digital integrated care system to support older adults with multimorbidity
- Licensed.



Traditional Healthcare		ProACT Integrated Healthcare Approach
Provider – Centric Model		Patient – Centric Model
Individual, Physician Expertise		Collaborative, Consultative Model
One Size Fits All Treatment		Personalised Treatment
Unidirectional, Unstructured		Bi-directional, Organised
Centralised & Hospital Based		Decentralised & Community Based
Physician-Expertise Driven Model		Healthcare Analytics-Driven Model
Reactive Treatment of Disease		Proactive Prevention of Disease



# Case Example: Solvotrin Therapeutics

- **School of Pharmacy and Pharmaceutical Sciences**
- Prof. John Gilmer
- Iron supplements, Aspirin pro-drugs, Anti-inflammatory pipeline.
- TCD Campus Company.



Cork based Solvotrin Therapeutics announces exclusive US deal for Active Iron



MEDIAPLUS / 18TH MARCH 2025 / CORMAC CAHILL

# Industry Engagement



## AGENDA

1. Business Engagement Supports for Trinity Researchers
2. Why Partner with Industry
3. Engagement Pathways
4. Funding Mechanisms & Case Studies
5. Practical Steps
6. Portal@TrinityEast
7. Q&A

# Business Engagement Team & Supports for Trinity Researchers

**Dr Chris Keely (ckeely@tcd.ie)**

**Senior Business Manager**



**Dr Lyn Markey (lymarkey@tcd.ie)**

**Business Development Manager**



**Tony O'Callaghan (ocallaa5@tcd.ie)**

**Business Intelligence Analyst**



**Dr Jurgen Osing (osingju@tcd.ie)**

**Business Development Manager**



**The Business Development team works with PIs on:**

- ❖ Comprehensive guidance in developing your industry proposition
- ❖ Facilitating discussions with partners
- ❖ Identifying suitable engagement mechanisms
- ❖ Supporting through to successful launch of industry projects and beyond

# The Value of Partnering with Enterprise

## Why Partner with Industry?

### 1. Access to funding

- Funding from industry partner
- Industry-Academia Funding Schemes
- Portfolio of industry partners for future funding opportunities

### 2. Access to Resources

- Specialised equipment or technology
- Research expertise
- Datasets


### 3. Real World Impact

- Higher likelihood of translation into products, services, or clinical applications
- Opportunity to commercialise research
- Demonstrate impact for future grant applications

### 4. Employment portal for your researcher group

- Real-world project experience helps students have job-ready skills
- Network of industry contacts for researchers changing roles

# Partnership Staircase Model




# Pathways to Engage with Industry



**Collaborative Research**



**Consultancy**



**Knowledge Transfer**



**Contract Research**



**New Ventures**



**Talent**



**Education**



**Philanthropy**

# Typical Research Engagement Options

Each Mechanism has Pros & Cons – All require Contractual Agreements

- ❖ Fully Funded Collaborative Research Engagement
- ❖ Service Contracts or Consultancy Programmes
- ❖ Direct Industry Sponsorship Programmes
- ❖ Gifted Funds (under a contractual Framework or non-specified)
- ❖ SFI Partnerships Programmes – Fellowship and CTC's
- ❖ SFI Center Programmes – Cost-shared or industry leveraged (Core plus new Spokes)
- ❖ Non- Hosted SFI Center Programmes – Cost-shared or leveraged
- ❖ Enterprise Ireland - Innovation Partnerships & Vouchers
- ❖ IRC awards : Postdoctoral, Postgraduate and Enterprise Employee
- ❖ Enterprise Ireland Technology Centres
- ❖ Disruptive Technology & Innovation Funds (DTIF's)
- ❖ European Collaborations: Research pillars & Knowledge Innovation Clusters
- ❖ Joint Research Labs and In-kind Infrastructure: placements and indirect acce
- ❖ Talent Placements & Internships ; Co-location of staff and Industry R-in-R's
- ❖ Company centric activities i.e.. IDA Feasibility Awards




# Engaging Enterprise: Vouchers for Irish SMEs





## Enterprise Ireland Innovation Voucher

- ❖ Potential **total amount of €40k** in 4 stages of €10k (one is co-funded by company)
- ❖ Company applies, open call all year around
- ❖ SMEs (<250 employees) that are based in Ireland are eligible.
- ❖ Consultancy, testing, prototype development, desk-based research.
  - ❖ Voucher # 1 – Evaluate idea and provide recommendations
  - ❖ Voucher # 2 – Develop and Design Product and/or Service
  - ❖ Voucher # 3 – Build and Test etc



# Enterprise Fellowship Programs 2025



## Postgraduate Enterprise Partnership

- Co-funding call linking excellent researchers with enterprise
- Aims to support Masters or PhD researchers while based in the University
- Programme provides funding of €34,000 for 1-4 years to contribute towards:
  - Applicants' stipend (€25,000)
  - Postgraduate Registration (€5,750)
  - Research Expenses (€3,250)
- Co-funding is divided 2:1 Research Ireland: Industry (€22,700: €11,300)
- Enterprise partners can be a company, registered charity, social, cultural or not-for-profit civic organisation, state-owned enterprise or eligible public body that will co-fund and co-supervise the researcher for the duration of the grant.

## Postdoctoral Enterprise Partnership Scheme Overview

- **Researcher based in the University** and has access to enterprise partner expertise and facilities
- Designed to provide researchers vital experience working with an organisation in their field of research
- Facilitate commercialisation and application of research
- **Enterprise Partner can be based anywhere in the world** – MNCs; SMEs, non-profits, state owned, and some public bodies are eligible
- 12 or 24-months full time
- Enterprise Partner contributes 1/3 value of the award - €22,000 - €27,500 annually depending on experience level
- Short application led by researcher with input from enterprise partner
- IP rights agreement to be put in place prior to commencement

# Engaging Enterprise: Irish based companies



## Innovation Partnership Program

- ❖ Grants of up to 80% towards eligible costs of the research project
- ❖ Essentially open call – one deadline per month
- ❖ Companies based in Ireland are eligible (EI/IDA/UnaG/LEO Client)
- ❖ Company to access expertise and resources to undertake research towards the development of new and improved products, processes, services, and generate new knowledge and know-how
- ❖ Projects run for up to 24 months

Type of Research	Company Size		
	Small company	Medium company	Large company
<i>Industrial Collaborative Research</i>	80%	75%	65%
<i>Experimental Collaborative Development</i>	60%	50%	40%

# INNOVATION

# PARTNERSHIP



Prof John O' Leary

## IPP : Delivering Tomorrow's Diagnostics Today

- ❑ Develop capacity @ Company around NGS for molecular typing of viruses allowing full epidemiological tracing.
- ❑ Develop New Expertise in the Molecular Diagnostics sector in Ireland.

	Company Size		
Type of Research	Small Company	Medium Company	Large Company
Industrial Collaborative Research	20% cash	20% cash plus 5% cash/in-kind	20% cash plus 15% cash/in-kind
Experimental Collaborative Development	20% cash plus 20% cash/in-kind	20% cash plus 30% cash/in-kind	20% cash plus 40% cash/in-kind

Each company partner will be expected to pay a minimum of 20% of the project costs in cash irrespective of company size or category of research

**INTELLECTUAL PROPERTY** :A Heads of Agreement Template' is completed and signed by both the research institute and the company at the application stage.

This outlines how Intellectual Property will be handled in advance of a full contract agreement

- ❑ Eurofins have a new shared diagnostics laboratory in TTMI @ St James.
- ❑ TTMI Researchers will have on-site access to latest instruments & Diagnostic toolkits.
- ❑ Both partners now looking at European and other National funding opportunities.

# Engaging Enterprise: Irish/ International Companies




## Strategic Partnership Program

- ❖ Typically €800k-6M+ and the programme can involve multiple partners. Partners can be international.
- ❖ Duration up to 5 years
- ❖ Eligible co-funding partners include companies, charities, philanthropic organisations, or a combination of these
- ❖ 50/50 cost-share model - RI provides matching funds to the total cash contribution from the industry partners.
- ❖ RI and Industry provide direct cash funding to the university at an overhead rate of 30% (versus 75% for fully funded projects).
- ❖ Open call with 2-stage application process with RI f-2-f engagement during phase-1 of the application.

# Strategic Partnership – Examples

## EYE-D: New treatments for Degenerative Retinal Diseases

Scale: €3.2M    Type: Cost Share 50%    Partners: Multiple



	Direct	RI Cost Share	Industry Cost Share	RI Overhead	Industry Overhead*	Total Project Value	Full Cost To Industry	Ave per year
SPP	€3,200,000	€1,600,000	€1,600,000	€480,000	€480,000	€4,160,000	€2,080,000	€520,000
IND Fully Funded	€3,200,000	0	€3,200,000	0	€2,400,000	€5,600,000	€5,600,000	€1,400,000

# Engaging Enterprise: Irish Companies



## Disruptive Technology Innovation Fund (DTIF)

DTIF is about funding **collaborations** that demonstrate **technology-based disruptive innovation**, that can:

- *Alter markets,*
- *Alter the way business operates,*
- *Involve new products or the emergence of new business models.*

- ❖ Funding: minimum €1.5M. No formal maximum, typically €2-8M
- ❖ Duration: up to 3 years, projects of shorter duration may be proposed where appropriate
- ❖ Cost-share model: 50% SMEs; 40% MNCs, 100% RPOs (Research Performing Org. – cannot receive >50% of funding)
- ❖ Eligible Companies : Based in Ireland & EI/IDA/Údarás na Gaeltachta Client
- ❖ Eligible Projects: at least 3 partners including one SME and another enterprise partner. The type of research must include ‘industrial research’ and/or ‘experimental development’ (within TRL 3-7)

# Industry Fully Funded Projects



## Fully Funded Collaborative Projects

- **Full economic rates apply** - Industry is charged at full overhead rate (**75% versus 30%** for co-funded collaborations)
- **Resourcing**
  - Consideration needs to be given on management, resources, deliverables & timelines
  - Hiring of Experienced PDRA or Research Fellows are really key to staff adequately
- **IP** – IP Rights typically favours the industry partners – SOW & Background IPR need careful consideration
- **Contracts** - Usually company will want their contract format to be use – not our preferred starting point
- **Location** - Industry can be national or international enterprises

# Key Considerations before Engaging with Industry

## IP – protect your intellectual property!

- Is there an NDA in place before discussions begin?
- Industry partners' IP expectations?
- Other considerations- Publication rights; Data or material transfers;

## Budgets

- Contingency fund and timelines
- Overhead rates
- Project governance

## Funding

- Fully funded/Cost Shared
- Company cash and in-kind supports

Engage the Industry Team early – We're always here to support

# Portal@Trinity East – A New Innovation Hub

- An Innovation & Enterprise Hub where industry, academia, start-ups and the wider community can meet, co-create and innovate.
- 4 Grand Canal Quay (4GCQ), Trinity East Campus.
- Incubation & Acceleration, Funding & Mentorship, Networks & Partnerships, Events & Facilities.





**Questions**



**Trinity College Dublin**  
Coláiste na Tríonóide, Baile Átha Cliath  
The University of Dublin

# Thank you



**Dr Lyn Markey ([lymarkey@tcd.ie](mailto:lymarkey@tcd.ie))**  
**Business Development Manager**



**Dr Chris Keely ([ckeely@tcd.ie](mailto:ckeely@tcd.ie))**  
**Senior Business Manager**



**Mr. Eoin Kieran ([kierane@tcd.ie](mailto:kierane@tcd.ie))**  
**Knowledge Transfer Case Officer**



**Dr. Gordon Elliott ([Gordon.Elliott@tcd.ie](mailto:Gordon.Elliott@tcd.ie))**  
**Senior Knowledge Transfer Case Manager –  
Health Sciences and MedTech**

